AbbVie Management

Management criteria checks 1/4

AbbVie's CEO is Robert Michael, appointed in Jul 2024, has a tenure of less than a year. total yearly compensation is $14.44M, comprised of 9.9% salary and 90.1% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth MX$347.54M. The average tenure of the management team and the board of directors is 1.2 years and 11.9 years respectively.

Key information

Robert Michael

Chief executive officer

US$14.4m

Total compensation

CEO salary percentage	9.9%
CEO tenure	less than a year
CEO ownership	0.006%
Management average tenure	1.2yrs
Board average tenure	11.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Robert Michael's remuneration changed compared to AbbVie's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	US$5b
Jun 30 2024	n/a	n/a	US$5b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$14m	US$1m	US$5b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$9b
Mar 31 2023	n/a	n/a	US$8b
Dec 31 2022	US$10m	US$1m	US$12b
Sep 30 2022	n/a	n/a	US$13b
Jun 30 2022	n/a	n/a	US$13b
Mar 31 2022	n/a	n/a	US$12b
Dec 31 2021	US$12m	US$1m	US$11b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$7b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$13m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$8b
Dec 31 2019	US$9m	US$907k	US$8b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$5b
Dec 31 2018	US$3m	US$554k	US$6b

Compensation vs Market: Robert's total compensation ($USD14.44M) is above average for companies of similar size in the MX market ($USD5.72M).

Compensation vs Earnings: Robert's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Robert Michael (54 yo)

less than a year

Tenure

US$14,441,320

Compensation

Mr. Robert A. Michael served as Chief Operating Officer at AbbVie Inc. since June 29, 2023 until July 01, 2024 and served as its President since June 23, 2022 until July 01, 2024 also serves as its CEO and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Richard Gonzalez	Executive Chairman	11.9yrs	US$25.66m	0.022% MX$ 1.4b
Robert Michael	CEO & Director	less than a year	US$14.44m	0.0056% MX$ 347.5m
Scott Reents	Executive VP & CFO	2.5yrs	US$10.19m	0.00087% MX$ 54.2m
Azita Saleki-Gerhardt	Executive VP & COO	less than a year	US$9.30m	0.011% MX$ 706.9m
Jeffrey Stewart	Executive VP & Chief Commercial Officer	no data	US$15.35m	0.0035% MX$ 219.2m
Roopal Thakkar	Executive VP of Research and Development & Chief Scientific Officer	less than a year	no data	0.00092% MX$ 57.3m
Elizabeth Shea	Senior Vice President of Investor Relations	no data	no data	no data
Perry Siatis	Executive VP	2.2yrs	no data	0% MX$ 0
Sanjay Narayan	Senior VP	1.2yrs	no data	no data
Timothy Richmond	Executive VP & Chief Human Resources Officer	no data	US$3.30m	0.00078% MX$ 48.6m
Wulff-Erik von Borcke	Senior VP of AbbVie & President of Oncology	1.2yrs	no data	no data
Nicholas Donoghoe	Executive VP and Chief Business & Strategy Officer	1.9yrs	no data	0.0032% MX$ 196.8m

1.2yrs

Average Tenure

55yo

Average Age

Experienced Management: ABBV *'s management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Richard Gonzalez	Executive Chairman	11.9yrs	US$25.66m	0.022% MX$ 1.4b
Robert Michael	CEO & Director	less than a year	US$14.44m	0.0056% MX$ 347.5m
Roxanne Austin	Lead Independent Director	11.9yrs	US$388.39k	0.00065% MX$ 40.5m
Thomas Freyman	Independent Director	4.6yrs	US$389.98k	0.0071% MX$ 441.6m
Glenn Tilton	Independent Director	11.9yrs	US$421.58k	0.0014% MX$ 87.8m
Edward Rapp	Independent Director	11.9yrs	US$394.98k	0.00090% MX$ 56.1m
William H. Burnside	Independent Director	11.9yrs	US$377.48k	0% MX$ 0
Frederick Waddell	Independent Director	11.9yrs	US$369.98k	0.00011% MX$ 6.9m
Melody Meyer	Independent Director	7.6yrs	US$369.98k	0% MX$ 0
Brett Hart	Independent Director	8.9yrs	US$384.98k	0% MX$ 0
Rebecca Roberts	Independent Director	6.6yrs	US$359.98k	no data
Robert Alpern	Independent Director	11.9yrs	US$461.18k	0.000010% MX$ 622.8k

11.9yrs

Average Tenure

70yo

Average Age

Experienced Board: ABBV *'s board of directors are seasoned and experienced ( 11.9 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 17:42
End of Day Share Price	2024/12/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AbbVie Inc. is covered by 54 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Ishan Majumdar	Baptista Research
Luisa Hector	Berenberg

AbbVie Management

Management criteria checks 1/4

Key information

Recent management updates

Executive Chairman recently sold Mex$242m worth of stock

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

AbbVie Announces Board Changes

AbbVie Inc. Announces Board of Directors Changes

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

Recent updates

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Nimble Therapeutics, Inc. from Telegraph Hill Partners and Roche Venture Fund for $200 million.

AbbVie Inc. (NYSE:ABBV) complete the acquisition of Aliada Therapeutics, Inc. from Johnson & Johnson Innovation - JJDC, Inc., RA Capital Management, L.P., RA Ventures, OrbiMed Advisors LLC and Sanofi Ventures.

Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma

AbbVie Inc. Announces Updated Results from the Phase 1b/2 EPCORE® NHL-2 Trial Evaluating Fixed-Duration Investigational Epcoritamab

Abbvie Receives European Commission Approval of Elahere (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter dividend of US$1.64 announced

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025

Third quarter 2024 earnings released: EPS: US$0.88 (vs US$1.00 in 3Q 2023)

AbbVie Inc. (NYSE:ABBV) entered into an agreement to acquire Aliada Therapeutics, Inc. for $1.4 billion.

U.S. FDA Approves AbbVie (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson's Disease

Upcoming dividend of US$1.55 per share

Allergan Aesthetics Announces Availability of Juvederm Voluma Xc for Moderate to Severe Temple Hollowing

AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024

Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Second quarter dividend of US$1.55 announced

AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process

Executive Chairman recently sold Mex$242m worth of stock

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

New minor risk - Profit margin trend

Second quarter 2024 earnings released: EPS: US$0.77 (vs US$1.14 in 2Q 2023)

AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

Upcoming dividend of US$1.55 per share

AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024

AbbVie Announces Board Changes

AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

First quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

AbbVie Inc. Announces Board of Directors Changes

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

Investor sentiment improves as stock rises 16%

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Health Canada Approves QULIPTA (atogepant) for the Preventive Treatment of Chronic Migraine in Adults

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

First quarter 2024 earnings released: EPS: US$0.77 (vs US$0.13 in 1Q 2023)

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources